AI-generated analysis. Always verify with the original filing.
Vor Biopharma Inc. entered into a Securities Purchase Agreement with entities affiliated with TCGX for a private placement of 5,338,078 shares of common stock at $14.05 per share, raising approximately $75.0 million in gross proceeds. The company intends to use the net proceeds to advance development of its clinical pipeline and for general corporate purposes.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Ag
Unregistered Sales of Equity Securities. The disclosures set forth in Item 1.01 above regarding the Private Placement are incorporated into this Item 3.02. The
, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Form of Securities Purchase Agreement. 10.2 Form of Registration Rights Agreement.
Material Agreement